

## Yale Liver Center Research Seminar

*Presented by Yale School of Medicine,  
Department of Internal Medicine*

# Immunogenomic profiling of cholangiocarcinoma: towards the identification of novel therapeutic opportunities



**Daniela Sia, PhD**

Assistant Professor

Division of Liver Diseases; Department of Medicine

Tisch Cancer Institute

Icahn School of Medicine at Mount Sinai

**Tuesday, June 7, 2022**

**5:00-6:00PM**

Host: Mario Strazzabosco,  
MD, PhD

**\*Hybrid event\***

In-person location:

**Fitkin Amphitheatre**

Zoom link:

<https://zoom.us/j/98120531831?pwd=Z2Z4Zi9MbDFSvmSrK3Jsa0IxdWVMUT09&from=addon>

Meeting ID: 981 2053 1831

Passcode: 691827

To record your attendance to this activity, text the Activity Code (29451) to 203-442-9435.

**There is no corporate support for this activity. Accreditation:** The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** NEED to understand the current genetic landscape of intrahepatic cholangiocarcinoma (iCCA) and its impact on the management of the disease. - NEED to understand previous patients' stratification based on molecular features. NEED to understand more recent effort to integrate genomics and immunophenotyping of iCCA and their impact on novel potential therapeutic strategies. **Objectives:** 1. Demonstrate awareness of the current management of iCCA. 2. Describe the molecular landscape of iCCA. 3. Demonstrate awareness of future potential therapeutic approaches. **Faculty Disclosures:** D. Sia, faculty/planner for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose. M. Strazzabosco, faculty/planner for this educational event, is a consultant for Engitix. All of the relevant financial relationships listed for these individuals have been mitigated. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**